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Claire M Wagner6, Cameron T Nutt10 and Agnes Binagwaho7,8,9Products with high efficacy and low cost are desirable in
all market sectors and environments, particularly in
settings where resources are limited. The health sectors
of developing nations are an example of this basic eco-
nomic principle as constrained financial and human re-
sources must be budgeted toward large (and often,
growing) populations’ health needs. However, the cost
and quality characteristics that are absolutely necessary
in resource-limited settings (RLS) remain highly desir-
able in wealthy markets as well. Consequently, techno-
logies and strategies designed in RLS are frequently
adopted by high-income nations, a process termed
“reverse innovation” [1-4].
In recent years, some medical and surgical devices
designed for RLS have been adopted by high-income
nations. These reverse innovations have simultaneously
overcome historical barriers to medical device deploy-
ment in RLS and challenged previously held assump-
tions regarding the direction of information transfer
between high- and low-income nations. The potential
for reverse innovation has subsequently been proposed as
a reason in and of itself to develop products for RLS [4].
Products that result in reverse innovation offer improved
care quality and treatment outcomes at lower costs to
health care systems, expand markets for manufacturers,
promote bidirectional transfer of information, and
strengthen global partnerships for health equity [1-4].
One country that has made investments in myriad
health innovations is Rwanda, a landlocked East African
nation of approximately 12 million. Within the past two
decades, Rwanda’s limited resources and diverse health* Correspondence: gmody@partners.org
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tions ranging from community-based service delivery
pathways to novel vaccine roll-out strategies [5-10].
Rwanda’s innovative approaches to seemingly insurmount-
able health challenges, and the nation’s resounding suc-
cesses in these initiatives, have been described in a previous
article in this Globalization and Health special series [2].
In the present article, we describe our experience with
medical device innovation in Rwanda through two case
studies, highlighting approaches taken to accelerate
development and facilitate bidirectional flow of informa-
tion. We also discuss ongoing challenges to progress in
the field of health technology innovation for RLS. In
sharing our experiences, we add our voices to the call
for health technology innovation for low- and middle-
income countries (LMICs).
Case study: Wound-Pump
The Wound-Pump is a mechanically-powered simplified
negative pressure wound therapy (sNPWT) device that
applies a vacuum to a wound dressing. Initially conceived in
2007 and manufactured by WiCare Solutions, design features
of the Wound-Pump address several inadequacies of other
sNPWT systems for use in LMICs. Electrically powered
Negative Pressure Wound Therapy (NPWT) systems have
been proven to speed wound healing in diverse settings
around the world, providing cleaner, less painful and more
convenient hospital- and home-based wound treatment
compared to conventional methods [11,12]. Non-healing
wounds are ubiquitous, and create a clinical need for
NPWT systems in developed and developing areas alike
[13,14]. The authors’ clinical experiences through partici-
pation in long-standing partnerships between institutions
based in Rwanda and the United States indicated the need
for practical and affordable wound therapies in Rwanda.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Mechanically powered Wound-Pump design.
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desired clinical results, cost and power supply have lim-
ited access to these therapies in RLS, including Rwanda
[13,14].
The Wound-Pump was developed between 2007 and
2012 through a multidisciplinary design process in which
the project engineer and clinical staff conducted extensive
field testing in LMICs. The Wound-Pump has undergone
testing to establish safety and biomechanical performance
in Rwanda (ClinicalTrials.gov ID NCT01339429), and is
currently undergoing clinical use approval process. Once
manufacturing and distribution are completed, wound
treatment with the Wound-Pump will be initiated in refer-
ral and district hospitals and subsequently maintained by
community health workers at home and in health centers.
In addition to establishing safety and efficacy, however,
the Wound-Pump design process addressed several chal-
lenges that have prevented market penetration by similar
products. In particular, access to device materials and a
dependable electrical supply have limited uptake of
NPWT systems in many LMICs. Even in environments
where the requisite materials and electrical supply are
available, prohibitively high device costs may limit access
to otherwise suitable technologies. Another non-electrical
sNPWT system, SNaP, manufactured by Spiracur, encoun-
tered these challenges during trials in Tanzania: despite its
ability to operate without electricity, limited distribution
channels for its highly specialized, spring-powered compo-
nents and high prices (180–200 USD/device) created ob-
stacles to scaling up use of the system [15,16].
In contrast to the SNaP system design process in the
United States, development of the Wound-Pump system
in LMICs allowed product assessment and modification in
the environments in the settings in which the device will
be deployed. Due to limited electrical supply in target
regions, the Wound-Pump is mechanically powered,
employing a bellows hand-pump is used to apply a
vacuum to an airtight wound dressing (Figure 1) [14].
Unlike the SNaP system, however, the Wound-Pump sys-
tem incorporates reusable materials that are or will be
easy to obtain anywhere in the world. Furthermore, the
Wound-Pump can be manufactured for less than 3 USD
per device, drastically reducing consumer costs [14].
Field-based product testing also allowed early identifica-
tion of potential device failures. The original Wound-
Pump device prototype utilized a dressing design similar
to that employed by other mechanically powered sNPWT
systems [17], which was shown to be effective in maintain-
ing suction with the bellows hand pump under laboratory
conditions [13]. Our experience with the Wound-Pump in
Haiti following the 2010 earthquake quickly demonstrated
existing dressing designs to be ineffective on contoured
body locations and in hot and humid climates when
coupled with the bellows power source, however. Aflexible polymer was therefore added to seal the dressing
to the skin, the dressing was incrementally modified to ad-
dress new issues identified by point of care clinical staff –
such as patient immobility in external bone fixation de-
vices and healthcare worker technical skill in applying
dressings – over the course of clinical trials in Rwanda.
Through this process, the dressing design was finalized
within two years of initiating trials.
Case study: PrePex male circumcision device
The PrePex device offers a non-surgical method for per-
forming male circumcision (MC). MC is proven to be effect-
ive in reducing the lifetime risk of HIV infection by up 60%
in males [18-22]; the United Nations Programme on HIV/
AIDS (UNAIDS) has set a target of 20 million MCs by 2015
[23]. The PrePex device has met prequalification require-
ments of the World Health Organization (WHO) for use
in the developing world [24], and has received approvals
from the Conformité Européenne mark (CE mark), United
States Food and Drug Administration (US FDA), and the
International Organization for Standardization (ISO).
The design of the PrePex device offers numerous advan-
tages over traditional surgical MC in LMICs. Surgical MC
is accomplished by cutting the foreskin and requires
anesthesia, sterile environments and trained health care
providers – all barriers to MC in the developing world [25].
The PrePex device, invented in Israel by Circ MedTech and
subsequently trialed in Rwanda, involves concentric rigid
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to the distal portions of the foreskin (Figure 2). The de-
vice remains in place for one week while the ischemic
foreskin necroses, after which the device and the nec-
rotic foreskin can be painlessly removed [26-28]. Fur-
thermore, MC with PrePex is cost effective compared
to surgical MC, especially in areas where national regu-
lations allow the PrePex procedure to be performed by
non-physician health care personnel [29,30]. The flexi-
bility to perform MC with the PrePex device under
non-sterile conditions expands the variety of settings in
which the device may be deployed, and the brief pro-
cedure times (typically less than 5 minutes, including
preparation) allow high patient throughput [27,28].
Field-based testing to establish the safety and efficacy
of the PrePex device and the procedure for its clinical
use occurred through a series of trials led by the Minis-
try of Health (MoH) of Rwanda [26-28]. These sequen-
tial studies adapted the PrePex device placement and
removal procedures to minimize the complexity of the
procedures, and optimize clinical outcomes and patient
satisfaction. Since these initial studies, local PrePex ex-
perts have led training for professional use of the device
in Rwanda; the MoH has trained 13 medical doctors
and 48 nurses to use the PrePex device and is actively
training more. Additional field-based research con-
ducted in Rwanda also demonstrated the feasibility of
device use by non-physician health care providers and
acceptability of MC by PrePex to target populations
[28]. The device is now being used in district hospitals
and health centers as part of a comprehensive package
of national HIV prevention strategies, and, through its
use in campaigns, seems to have increased demand for
MC among Rwandan youth [27,28]. The 2013 Rwanda
HIV and AIDS National Strategic Plan has set a goal of
providing voluntary MC to 700,000 males by 2015, and
scaling up MC services is anticipated to play a key roleFigure 2 Components of the Prepex device.in the national target of reducing new annual HIV in-
fections by half by 2018 [31].
Elements of successful reverse innovation
The Wound-Pump and the PrePex device represent
two medical devices designed in and for LMICs with
characteristics that make them appealing to health care
systems in developed areas. These examples of medical
device reverse innovation resulted from a combination
of several successful elements in the approaches taken
to design, develop and deploy the devices.
First and foremost, both the Wound-Pump and Pre-
Pex devices offer solutions to current gaps in health
care delivery in target regions. In some cases, the health
threats to be addressed by a device may already be
identified in local and global health care goals and pri-
orities; such was the case with the PrePex device, which
has the potential to reduce HIV transmission and so
achieve Millennium Development Goal 6 [23,32]. Data
on lower profile conditions are often lacking, however.
We therefore emphasize the value of clinicians’ profes-
sional experience as a key source for identifying highly
morbid and mortal conditions affecting vulnerable pop-
ulations. Especially when coupled with information
sourced from published literature, firsthand experience
in the clinical settings can contribute intimate know-
ledge of the needs and limitations of particular health
care delivery environments.
Such knowledge is also indispensable during rigorous
device design processes in which barriers to successful
use of devices are addressed. Medical devices are often
unavailable or non-functional in RLS due to lack of
funds, materials, electrical power and maintenance
capabilities [13,14,33]. Through a deterministic design
process, clinical needs are deliberately broken down
into a series of engineering tasks, and creative design
solutions addressing existing barriers are developed
(Figure 3). A device’s design itself may not be simple –
device designs should achieve maximum impact ac-
cording to globally recognized best practices – but
technologies should also be unornamented and afford-
able in order to promote accessibility and adoption in
LMICs [1]. Paramount to the design process is an em-
phasis on equal partnership with local clinicians and
institutions where the device will be used. Exchange of
feedback should be natural and welcomed, as many de-
vice developers actively practice and maintain teaching
and training relationships in the clinical environments
where the devices will be deployed.
Through such a process, key design issues encoun-
tered during the translation of promising ideas to point
of care medical devices are addressed early and in a col-
laborative fashion. The deterministic design process is
well illustrated by both the Wound-Pump and the
Figure 3 Globally responsible device designs require a deterministic
process to translate clinical needs into an innovation that meets the
requirements of the local environment.
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were made to accommodate human, financial and mater-
ial resource limitations in target regions: the Wound-
Pump is mechanically rather than electrically powered
and contains reusable components, and the PrePex device
can be employed without anesthesia or advanced surgical
training.
Once local barriers to device use have been identified
and addressed, field-based product testing is of critical im-
portance to innovative device success. Prototype refine-
ment can be accelerated by designing clinical trials to
include stopping rules, embedded pilots, and quality
checks. Field-based testing allows early detection of un-
anticipated complications in device deployment or per-
formance, such as the ineffective dressing design originally
employed in initial models of the Wound-Pump sNPWT
system. Field-based testing also lends insight into the
feasibility of device deployment in specific clinical envi-
ronments and acceptability to potential patient popula-
tions, as was the case with early testing of the PrePex
device in Rwanda.
Critical to the proper field testing of these devices is an
in-country institutional review board with the authority to
approve and terminate studies. In Rwanda, the National
Ethics Committee is charged with review of all studies. At
the conclusion of a study, results are mandatorily reported
to the MoH and all participating partners. Budgets and
timelines for device development must take these import-
ant steps, including additional unplanned testing phases,
into account.The final component of device innovation is seeing the
device to market and use. Bidirectional partnerships and
development of “local growth teams” are key strategies to
achieving effective local implementation [34,35]. In our
experience, device innovation in conjunction with local,
field-based teams can serve as motivation for local health
care providers by engaging their interest and creativity,
thereby mitigating the drive behind the brain drain ob-
served in LMICs [36,37]. Most importantly, truly sustain-
able implementation requires incorporation of the device
into coordinated local health systems strengthening ef-
forts, such as the Rwandan Human Resources for Health
program [38].
Challenges to medical device reverse innovation
and scale up
Numerous challenges exist to scaling up use of novel
medical devices. Sustainable funding for device implemen-
tation in LMICs remains an enormous challenge, espe-
cially for conditions neglected by global health funders,
such as non-communicable diseases and injuries [1,39].
In-country manufacturing can keep distribution costs low
and stimulate local economic growth in low-income set-
tings, but for local manufacturing to be cost-effective it
must be driven by appropriate infrastructure, accessible
materials, supply chains, finances, and sustainable market
demands and distribution channels.
Furthermore, international regulatory agencies maintain
strict requirements to mitigate potential risks based on
the class of a device; innovation of low-cost devices may
be threatened by packaging requirements, shelf-life limita-
tions, and other requirements imposed by regulators.
While safety and high quality care must be maintained at
all times throughout the testing and prototyping process,
opportunities to adjust to local contexts have included the
allowance of certain device components to be completely
sterilized and reused. In understaffed health care facilities,
family members often play a role in monitoring the pa-
tient once the patient is stable. Approval processes should
take these contextually relevant considerations into ac-
count, and companies designing medical devices intended
for use in LMICs should submit for global use approvals
that account for the local realities that may affect device
use.
Conclusion
To the extent that reverse innovation may spur develop-
ment of health technologies, it is likely to be an extremely
positive force in the global health equity movement. Add-
itionally, international industries may stand to benefit
from low-margin, high volume models that enhance reach
and access by selling larger quantities of less expensive de-
vices to emerging markets via subsidiaries and in partner-
ship with the local private sector or through public-private
Mody et al. Globalization and Health  (2015) 11:20 Page 5 of 6relationships. The resulting local economic opportunities
could also stimulate local health care systems.
We urge the global health community and health tech-
nology industry to seek opportunities for novel medical
device development to accompany global health efforts.
There are many challenges inherent in this work, includ-
ing limitations to infrastructure, materials, financing, mar-
ket demands, and distribution channels, among others.
But the process of navigating through and overcoming
these challenges can often produce the most innovative
solutions, and these solutions may be applicable in many
settings. Ultimately, we believe global medical device
innovation will improve access to care for all people,
including the poorest and most disadvantaged, and we ad-
vocate for a defined and feasible pathway from need iden-
tification to device implementation and all the steps in
between.
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